Press Releases



Mediclinic Intnl plc - Director/PDMR Shareholding

18/06/2018
RNS Number : 6908R
Mediclinic International plc
18 June 2018
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

 

18 June 2018

 

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

Awards granted under the Company's Short-Term Incentive Scheme
 and Long-Term Incentive Plan

 

On 15 June 2018, awards over ordinary shares in Mediclinic (the "Shares") were granted to the following Directors and other persons discharging managerial responsibilities ("PDMRs") under the Company's Short-Term Incentive Scheme (the "STI") and Long-Term Incentive Plan (the "LTIP"), approved by shareholders in July 2017:

 

Name

 

Director/ PDMR

Number of Shares awarded under the STI

Number of Shares awarded under the LTIP

Dr Ronnie van der Merwe

Director

n/a

200,128

Jurgens Myburgh

Director

27,236

110,646

Danie Meintjes

Director

45,811

209,998

David Hadley

PDMR

n/a

26,422

Gert Hattingh

PDMR

n/a

43,956

Magnus Oetiker

PDMR

n/a

59,701

Koert Pretorius

PDMR

n/a

48,121

Dr Dirk le Roux

PDMR

n/a

34,586

Dr Ole Wiesinger

PDMR

n/a

32,409

 

The awards made under the STI and LTIP were granted for nil consideration and are based on the average of the middle-market quotations of a Share during a period of five dealing days ending with the dealing day before the day of grant, which equates to £5.58 per Share.

 

The vesting of awards under the STI is subject to employment conditions only; no further performance conditions apply. Awards granted under the LTIP are structured as conditional awards, with vesting being subject to the satisfaction of performance conditions over a three-year period. Executive Directors of Mediclinic will be required to hold vested awards for a further two years (i.e. until the fifth anniversary of grant).

 

The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Dr Carel Aron van der Merwe

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

200,128

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

200,128

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Petrus Jurgens Myburgh

 

2.

Reason for the notification

 

a)

Position / status

Chief Financial Officer of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short Term Incentive Scheme

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

27,236

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

27,236

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

110,646

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

110,646

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Daniël Petrus Meintjes

 

2.

Reason for the notification

 

a)

Position / status

Executive Director of the Company

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short Term Incentive Scheme

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

45,811

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

45,811

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

209,998

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

209,998

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

David John Hadley

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer - Mediclinic Middle East

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

26,422

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

26,422

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Gert Cornelis Hattingh

 

2.

Reason for the notification

 

a)

Position / status

Chief Corporate Services Officer of the Mediclinic Group

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

43,956

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

43,956

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Magnus Ulrich Oetiker

 

2.

Reason for the notification

 

a)

Position / status

Chief Human Resources Officer of the Mediclinic Group

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

59,701

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

59,701

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Koert Hendrik Stefanus Pretorius

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer - Mediclinic Southern Africa

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

48,121

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

48,121

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Dr Dirk Cornelius le Roux

 

2.

Reason for the notification

 

a)

Position / status

Chief Information Officer of the Mediclinic Group

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

34,586

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

34,586

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

 

1.

Details of PDMR / person closely associated with them ("PCA")

 

a)

Name

Dr Thorsten Ole Wiesinger

 

2.

Reason for the notification

 

a)

Position / status

Chief Executive Officer - Hirslanden

 

b)

Initial notification / amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

 

b)

LEI

2138002S5BSBIZTD5I60

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification Code

Ordinary Shares

 

 

GB00B8HX8Z88

 

b)

Nature of the transaction

Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long Term Incentive Plan

 

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

£nil

32,409

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

 

 

32,409

 

£nil

 

e)

Date of the transaction

15 June 2018

 

f)

Place of the transaction

Outside a trading venue

 

 


 

 

About Mediclinic International plc

 

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

 

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

  Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGIGDLBXBBGII